Antiviral activity of a biologically active additive based on the extract of aspen bark in relation to the SARS-CoV-2 in experiments in vivo
- Authors: Burkova V.N.1, Sergun V.P.1, Ivanov A.A.1, Pyankov O.V.2
-
Affiliations:
- “Biolit” LLC
- State Scientific Center of Virology and Biotechnology “Vector”
- Issue: Vol 26, No 8 (2023)
- Pages: 44-50
- Section: Problems of experimental biology and medicine
- URL: https://bakhtiniada.ru/1560-9596/article/view/250538
- DOI: https://doi.org/10.29296/25877313-2023-08-06
- ID: 250538
Cite item
Open Access
Access granted
Subscription Access
Abstract
Purpose of the research. Study of antiviral activity, determination of a safe and effective dose of a dietary supplement based on aspen bark extract against the SARS-CoV-2 virus in a Syrian hamster model.
Material and methods. The object of the study was a biologically active food supplement based on an extract of aspen bark (Populus tremula L.), containing a concentrated aqueous extract of aspen bark and dihydroquercetin. We used a strain of coronavirus homologous to the early strain of human SARS-CoV-2, Wuhan-Hu-1, obtained from the State Collection of Viral Infections and Rickettsiosis of the FBRI SRC VB «Vector» of Rospotrebnadzor. The study of antiviral activity was carried out on Syrian hamsters (Mesocricetus auratus) obtained from the nursery of laboratory animals of the FBRI SRC VB «Vector» of Rospotrebnadzor, according to the following parameters: the amount of virus RNA (viral load) and the infectious titer of the virus in the tissues of the lungs and nasal cavity.
Results. It was established that under the indicated conditions of therapy, an effective safe daily dose of the drug based on aspen bark extract is a dose of 2000 mg/kg – on the fourth day after infection, virus replication on the nasal mucosa of infected animals significantly decreased by 3 times and the infectious titer of the virus – by 43 times. With an increase in the daily dose to 4000 mg / kg, signs of a toxic effect were observed. The minimum therapeutic daily dosage of the drug in the early period after infection with respect to SARS-CoV-2 was determined - at a daily dose of 250 mg/kg, the drug significantly reduced the viral load in the tissues of the nasal cavity by 6.6 times and the infectious titer by 12.5 times.
Conclusions. As a result of in vivo studies, it has been shown that a biologically active food supplement based on aspen bark extract has antiviral activity against the SARS-CoV-2 virus.
Full Text
##article.viewOnOriginalSite##About the authors
V. N. Burkova
“Biolit” LLC
Email: infobiolit@yandex.ru
Ph.D. (Chem.), Director of Science and Innovation
Russian Federation, TomskV. P. Sergun
“Biolit” LLC
Email: infobiolit@yandex.ru
Ph.D. (Chem.), Director
Russian Federation, TomskA. A. Ivanov
“Biolit” LLC
Author for correspondence.
Email: infobiolit@yandex.ru
Ph.D. (Chem.), Head of Research Department
Russian Federation, TomskO. V. Pyankov
State Scientific Center of Virology and Biotechnology “Vector”
Email: infobiolit@yandex.ru
Ph.D. (Biol.), Head of the Department “Collection of Microorganisms”
Russian Federation, Kol’tsovo, Novosibirsk RegionReferences
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. The New England Journal of Medicine. 2020; 382(8): 727–733.
- World Health Organization. WHO Coronavirus (COVID-19) dashboard (Cited 01 Apr 2023). [Internet]. Available from: https://covid19.who.int.
- Tay M.Z., Poh C.M., Rénia L., et al. The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology. 2020; 20(6): 363–374.
- Guan W.J., Ni Z.Y., Hu Y., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. The New England Journal of Medicine. 2020; 382: 1708–1720.
- Makashova V.V., Ponezheva Zh.B., Omarova H.G. i dr. Opyt primenenija Populina s digidrokvercetinom pri novoj koronavirusnoj infekcii. Jepidemiologija i infekcionnye bolezni. Aktual'nye voprosy. 2022; 2: 77–82.
- Maisonnasse P., Guedj J., Behillil S., et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature. 2020; 585(7826): 584–587.
- Chan J.F.W., Zhang A.J., Yuan S., et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden Syrian hamster model: Implications for disease pathogenesis and transmissibility. Clinical Infectious Diseases. 2020; 71(9): 2428–2446.
- Mironov A.N. Rukovodstvo po doklinicheskim issledovanijam lekarstvennyh sredstv. M.: FGBU «NCJeMSP». 2012. Т.1. 942 с.
- Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. American Journal of Epidemiology. 1938; 27(3): 493–497.
- Abrashova T.V., Gushhin Ja.A., Kovaleva M.A. i dr. Spravochnik. Fiziologicheskie, biohimicheskie i biometricheskie pokazateli normy jeksperimental'nyh zhivotnyh. SPB.: LEMA. 2013. 116 с.
- Gruber A.D., Firsching T.C., Trimpert J., et al. Hamster models of COVID-19 pneumonia reviewed: How human can they be? Veterinary pathology. 2022; 59(4): 528–545.
Supplementary files
